US EditionOrisDX Raises $4M Seed to Launch First-of-Its-Kind Saliva-Based Multiomic Platform, Targeting Oral Cancer - Journal of Cyber Policy
Summary by Journal of Cyber Policy
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
OrisDX Raises $4M Seed to Launch First-of-Its-Kind Saliva-Based Multiomic Platform, Targeting Oral Cancer - Journal of Cyber Policy
Pioneering saliva-based multiomic platform from Chicago secures $4M Seed from leading East and West coast investors to transform early oral cancer detection CHICAGO, IL, UNITED STATES, June 10, 2025 /EINPresswire.com/ — OrisDX, a precision diagnostics company spun out of the University of Chicago and an alumnus of the inaugural SMILE Health cohort, today announced the close of its $4M Seed financing round. This funding, led by Revere Partners an…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
